Top Industry News

The latest from CDMOs, CMOs, and suppliers featuring Veranova, Cytiva, Enzene, Kindeva, Delpharm, ReciBioPharm, Tjoapack and Tekniplex.   Chemicals/Chemical API Manufacturing * Veranova Breaks Ground on New ADC Mfg Facility; Adding Bioconjugation…

A roundup of bio/pharmaceutical partnering news from AstraZeneca/CSPC, Regeneron/Hansoh Pharma, Teva/Fosun Pharma, GSK/Bharat Biotech, and Astellas/Mitsubishi Research Institute.  * AstraZeneca, China’s CSPC in $5.3-Bn AI Drug-Development Pact* Regeneron, Hanosh Pharma…

The latest news on mergers and acquisitions featuring. Highlights below.  * Supernus Pharma to Acquire Sage Therapeutics in $795-M Deal * Regeneron Outbid for Genetic Testing Company 23andMe  Supernus Pharma to…

Bristol Myers Squibb (BMS) and BioNTech, a Mainz-Germany-based bio/pharmaceutical company, have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody, BNT327, across numerous solid…

UCB, a Brussels, Belgium-based bio/pharmaceutical company, has announced plans to build a new US-based biomanufacturing facility and to scale up its partnerships with US-based CDMOs.   The company says that the…

BioNTech, a Mainz, Germany-based bio/pharmaceutical company, has agreed to acquire CureVac, a Tubingen, Germany-based clinical-stage bio/pharmaceutical company specializing in mRNA cancer immunotherapies and vaccines, for $1.25 billion.   With the acquisition,…

The latest from CDMOs, CMOs, and suppliers featuring WuXi Biologics, Euroapi, Simtra BioPharma Solutions, MilliporeSigma, Made Scientific, PharmaLogic, Fujifilm, Antheia, Carbogen Amcis, Cellares, Mitsui, Schott Pharma and DuPont.   Chemicals/Chemical API…

A roundup of bio/pharmaceutical partnering news from Astellas/Evopoint Biosciences, Eli Lilly and Company/Camurus, Novo Nordisk/Deep Apple Therapeutics and Eli Lilly and Company/Juneva.  * Astellas, Evopoint Biosciences in $1.54-Bn ADC Pact *…

A roundup of news from Sanofi, AstraZeneca, the US Government and ADC Therapeutics. Highlights below.   * Sanofi, AstraZeneca Expand RSV Drug Production * HHS Revamps Vaccine Advisory Committee* US DOJ, FTC…

Sanofi has agreed to acquire Blueprint Medicines, a Cambridge, Massachusetts-based bio/pharmaceutical company specializing in rare diseases, in a $9.5-billion deal ($9.1 billion upfront and up to $400 million in milestone…